BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 22855175)

  • 1. CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.
    Sun H; Jia J; Wang X; Ma B; Di L; Song G; Ren J
    Clin Transl Oncol; 2013 Jan; 15(1):46-54. PubMed ID: 22855175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
    Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
    BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
    Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
    J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
    Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
    BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
    Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
    Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
    Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
    Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer.
    Buess M; Rajski M; Vogel-Durrer BM; Herrmann R; Rochlitz C
    Neoplasia; 2009 Oct; 11(10):987-1002. PubMed ID: 19794958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Vellon L; Menendez JA
    Cell Cycle; 2011 Nov; 10(22):3871-85. PubMed ID: 22127234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.
    Weitzenfeld P; Meshel T; Ben-Baruch A
    Oncotarget; 2016 Dec; 7(49):81123-81143. PubMed ID: 27835603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of human breast cancer CD44
    Qiao X; Zhang Y; Sun L; Ma Q; Yang J; Ai L; Xue J; Chen G; Zhang H; Ji C; Gu X; Lei H; Yang Y; Liu C
    Elife; 2021 Jul; 10():. PubMed ID: 34318746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction.
    Huang M; Li Y; Zhang H; Nan F
    J Exp Clin Cancer Res; 2010 Jun; 29(1):80. PubMed ID: 20569497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of CD44+CD24+ gastric cancer stem cells.
    Zhang C; Li C; He F; Cai Y; Yang H
    J Cancer Res Clin Oncol; 2011 Nov; 137(11):1679-86. PubMed ID: 21882047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are CD44
    Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
    Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.
    Vesuna F; Lisok A; Kimble B; Raman V
    Neoplasia; 2009 Dec; 11(12):1318-28. PubMed ID: 20019840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CD44
    Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
    Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.
    Leth-Larsen R; Terp MG; Christensen AG; Elias D; Kühlwein T; Jensen ON; Petersen OW; Ditzel HJ
    Mol Med; 2012 Sep; 18(1):1109-21. PubMed ID: 22692575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
    Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
    J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.